CalciMedica, Inc.
CalciMedica is dedicated to developing therapies for life-threatening inflammatory diseases affecting the pancreas, kidney, and lung. Their mission is to explore the therapeutic benefits of CRAC channel inhibitors to modulate immune response and protect against tissue injury, addressing high unmet medical needs with no current approved treatments.
Industries
Nr. of Employees
small (1-50)
CalciMedica, Inc.
505 Coast Boulevard South, Suite 307, La Jolla, CA 92037
Patents
Products
Intravenous small-molecule CRAC channel inhibitor (IV formulation)
An intravenously administered small-molecule CRAC channel inhibitor developed for acute, life-threatening inflammatory illnesses; characterized by dual activities of modulating immune cell activation and protecting organ tissue cells from calcium-mediated injury. Studied in multiple Phase 2 clinical trials in acute pancreatitis, acute respiratory distress syndrome / severe COVID-19 pneumonia, and acute kidney injury.
Oral small-molecule CRAC channel inhibitor candidates
Orally dosed CRAC channel inhibitor candidates in lead-optimization and IND-enabling preclinical testing, intended for chronic inflammatory indications such as chronic pancreatitis and rheumatoid arthritis.
Intravenous small-molecule CRAC channel inhibitor (IV formulation)
An intravenously administered small-molecule CRAC channel inhibitor developed for acute, life-threatening inflammatory illnesses; characterized by dual activities of modulating immune cell activation and protecting organ tissue cells from calcium-mediated injury. Studied in multiple Phase 2 clinical trials in acute pancreatitis, acute respiratory distress syndrome / severe COVID-19 pneumonia, and acute kidney injury.
Oral small-molecule CRAC channel inhibitor candidates
Orally dosed CRAC channel inhibitor candidates in lead-optimization and IND-enabling preclinical testing, intended for chronic inflammatory indications such as chronic pancreatitis and rheumatoid arthritis.
Services
Sponsor-led design and conduct of Phase 1 and Phase 2 clinical trials (randomized, double-blind, placebo-controlled and open-label designs), including protocol design, site and investigator collaboration, safety monitoring, and clinical data analysis.
Conduct of preclinical efficacy studies and IND-enabling testing in animal models of inflammatory organ injury, with associated biomarker assessments to support translational interpretation.
Sponsor-led design and conduct of Phase 1 and Phase 2 clinical trials (randomized, double-blind, placebo-controlled and open-label designs), including protocol design, site and investigator collaboration, safety monitoring, and clinical data analysis.
Conduct of preclinical efficacy studies and IND-enabling testing in animal models of inflammatory organ injury, with associated biomarker assessments to support translational interpretation.
Expertise Areas
- CRAC channel inhibitor drug discovery
- Small-molecule medicinal chemistry
- Formulation development for IV and oral small molecules
- Preclinical disease modeling for inflammatory organ injury
Key Technologies
- CRAC channel inhibition
- Small-molecule medicinal chemistry
- Intravenous small-molecule formulation
- Oral small-molecule lead optimization
News & Updates
June 12, 2025: CalciMedica announces an upcoming symposium at a major nephrology and critical care meeting.
May 14, 2025: The company reports financial results and updates on clinical progress.
April 17, 2025: The company announces upcoming medical meeting presentations.
CalciMedica's research focuses on CRAC channel inhibitors for inflammatory diseases of the pancreas, kidney, and lung.
June 12, 2025: CalciMedica announces an upcoming symposium at a major nephrology and critical care meeting.
May 14, 2025: The company reports financial results and updates on clinical progress.
April 17, 2025: The company announces upcoming medical meeting presentations.
CalciMedica's research focuses on CRAC channel inhibitors for inflammatory diseases of the pancreas, kidney, and lung.